According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA) has barred the company from making generic versions of an antiviral drug and an acid reflux medication. FDA reportedly said that “its original decisions granting tentative approvals were in error,” citing the “compliance status” of the company’s facilities. News sources indicate that the agency’s action is highly unusual and has occurred before in “rare circumstances” only. The loss of approval also means that the Indian drugmaker has lost the 180-day first-filer exclusivity for its versions of the popular drugs, which could affect its bottom line. Ranbaxy, which is currently being acquired in a $3.2-billion deal by Sun Pharmaceutical Industries, Ltd., reportedly said that it was evaluating “all available options to preserve its rights.” See The Wall Street Journal, Reuters, and Bloomberg BNA Product Safety & Liability Reporter™, November 6, 2014.